ATE135236T1 - Konjugate zur steigerung der durchlässigkeit der gefässe - Google Patents

Konjugate zur steigerung der durchlässigkeit der gefässe

Info

Publication number
ATE135236T1
ATE135236T1 AT89911955T AT89911955T ATE135236T1 AT E135236 T1 ATE135236 T1 AT E135236T1 AT 89911955 T AT89911955 T AT 89911955T AT 89911955 T AT89911955 T AT 89911955T AT E135236 T1 ATE135236 T1 AT E135236T1
Authority
AT
Austria
Prior art keywords
species
vasoactive
conjugates
disclosed
agent
Prior art date
Application number
AT89911955T
Other languages
English (en)
Inventor
Alan L Epstein
Michael M Glovsky
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Application granted granted Critical
Publication of ATE135236T1 publication Critical patent/ATE135236T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Distillation Of Fermentation Liquor, Processing Of Alcohols, Vinegar And Beer (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AT89911955T 1988-10-11 1989-10-11 Konjugate zur steigerung der durchlässigkeit der gefässe ATE135236T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25551388A 1988-10-11 1988-10-11
US41778289A 1989-10-04 1989-10-04

Publications (1)

Publication Number Publication Date
ATE135236T1 true ATE135236T1 (de) 1996-03-15

Family

ID=26944744

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89911955T ATE135236T1 (de) 1988-10-11 1989-10-11 Konjugate zur steigerung der durchlässigkeit der gefässe

Country Status (7)

Country Link
EP (1) EP0438497B1 (de)
JP (1) JP2961173B2 (de)
AT (1) ATE135236T1 (de)
AU (1) AU627785B2 (de)
DE (1) DE68925974T2 (de)
IL (1) IL91933A (de)
WO (1) WO1990003801A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2171392T3 (es) * 1990-08-29 2002-09-16 Ct Hospitalier Regional De Nan Poliligandos de proteina unidos a un nucleo de proteina estable.
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
DE69133036T2 (de) * 1990-11-09 2003-02-06 Stephen D. Gillies Cytokine immunokonjugate
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
DK0627940T3 (da) * 1992-03-05 2003-09-01 Univ Texas Anvendelse af immunokonjugater til diagnose og/eller terapi af vaskulariserede tumorer
US5660827A (en) * 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US7097839B1 (en) 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
AT409929B (de) * 1997-03-07 2002-12-27 Tritthart Helmut A Dr Polymere-infusionslösung zur anwendung bei der diagnose von tumoren, gegebenenfalls zu deren behandlung
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
CA2219961C (en) * 1998-01-09 2010-06-01 The University Of Southern California Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
DE19824653A1 (de) * 1998-02-25 1999-08-26 Schering Ag Nekrose-affine Verbindungen und ihre Verwendung zur Herstellung von Präparaten zur Pharmakotherapie
BR9909420A (pt) 1998-03-31 2001-09-25 Du Pont Pharm Co Composto, kit, composição metalofarmacêutica de diagnóstico ou terapêutica, composição de agente de contraste de ultrassom, composição radiofarmacêutica terapêutica e composição radiofarmacêutica de diagnóstico
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
NZ508873A (en) 1998-07-13 2003-10-31 Univ Texas Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
NZ511677A (en) 1998-12-18 2003-10-31 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals
WO2000035887A2 (en) 1998-12-18 2000-06-22 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6630120B1 (en) * 1999-03-08 2003-10-07 Alkermes, Inc. Agents to increase the uptake of pharmaceuticals and diagnostic substances into solid tumors
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
RU2263118C2 (ru) 1999-08-09 2005-10-27 Лексиген Фармасьютикэлс Корп. Комплексы антител с несколькими цитокинами
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
JP2003527398A (ja) * 2000-03-16 2003-09-16 ユニヴァーシティ オブ ピッツバーグ 内皮特異性ターゲティング
IT1318485B1 (it) * 2000-04-21 2003-08-25 Bracco Spa Uso di derivati di acidi biliari coniugati con complessi di ionimetallici nella visualizzazione diagnostica di sistemi microvascolari
US7517526B2 (en) 2000-06-29 2009-04-14 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
PT1366067E (pt) 2001-03-07 2012-11-29 Merck Patent Gmbh Tecnologia de expressão para proteínas contendo uma unidade de anticorpo de isotipo híbrido
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
DE60239454D1 (de) 2001-05-03 2011-04-28 Merck Patent Gmbh Rekombinanter, tumorspezifischer antikörper und dessen verwendung
AU2002357784B2 (en) 2001-12-04 2008-07-31 Merck Patent Gmbh Immunocytokines with modulated selectivity
ES2346205T3 (es) 2002-12-17 2010-10-13 Merck Patent Gmbh Anticuerpo humanizado (h14.18) del anticurpo 14.18 de raton que se enlaza con gd2 y su fusion con la il-2.
US20060222653A1 (en) * 2004-11-12 2006-10-05 Xencor, Inc. Antibodies operably linked to selected chemoattractants
US12226758B2 (en) 2020-11-11 2025-02-18 Ningbo Institute Of Materials Technology And Engineering, Chinese Academy Of Sciences Raney copper catalyst as well as preparation method and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
AU587600B2 (en) * 1985-01-11 1989-08-24 Regents Of The University Of California, The Method for preserving liposomes
US4724213A (en) * 1985-05-24 1988-02-09 Northwestern University Murine hybridoma Lym-1 and diagnostic antibody produced thereby
US4724212A (en) * 1985-05-24 1988-02-09 Northwestern University Murine hybridoma Lym-2 and diagnostic antibody produced thereby
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US4753895A (en) * 1987-02-24 1988-06-28 Hughes Aircraft Company Method of forming low leakage CMOS device on insulating substrate

Also Published As

Publication number Publication date
AU4424589A (en) 1990-05-01
WO1990003801A1 (en) 1990-04-19
AU627785B2 (en) 1992-09-03
IL91933A (en) 1994-12-29
EP0438497B1 (de) 1996-03-13
EP0438497A4 (en) 1992-02-26
DE68925974D1 (de) 1996-04-18
DE68925974T2 (de) 1996-11-14
JP2961173B2 (ja) 1999-10-12
EP0438497A1 (de) 1991-07-31
JPH04503945A (ja) 1992-07-16

Similar Documents

Publication Publication Date Title
ATE135236T1 (de) Konjugate zur steigerung der durchlässigkeit der gefässe
EP1704864B9 (de) Injizierbare Arzneimittelzubereitung bestehend aus einem Zytostatikum und einer durch einen Spacer gebundenen Maleinimidgruppe.
DE69010206D1 (de) Stabilisierte protein- oder peptidkonjugate.
Fiume et al. Drug targeting in antiviral chemotherapy: A chemically stable conjugate of 9-β-d-arabinofuranosyl-adenine 5'-monophosphate with lactosaminated albumin accomplishes a selective delivery of the drug to liver cells
EP0861667A3 (de) Partikelförmige Mittel
DE69812727D1 (de) Opioid-konjugate mit endogenen Trägerproteinen
DK651187A (da) Leveringsvehikel med amphiphil-associeret aktiv bestanddel og fremgangsmaade til dets fremstilling
WO1998022141A2 (en) Enhanced effects for hapten conjugated therapeutics
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
WO1999056723A3 (en) Hemoglobine-haptoglobin complexes for targeted drug delivery
WO1997025097A3 (en) Activatable infusable dispersions and methods for using them for therapy and diagnostics
JP2002535293A (ja) 無針の経皮的粉末薬物送達を増強する方法
DE69129463D1 (de) Verwendung von substanzen in partikelform
CA2000479A1 (en) Vasopermeability-enhancing conjugates
Ely Dermatologic therapies you’ve probably never heard of
Gruber et al. An implantable pump for intrarenal infusion of immunosuppressants in a canine autotransplant model
AU754117B2 (en) Targeting and prolonging association of drugs to the luminal surface of the pulmonary vascular endothelial cells
JPH06293631A (ja) ケラチン加水分解物を担体として用いたドラッグデリバリーシステム
JPS60226819A (ja) フイブロネクチン複合体
SU1033141A1 (ru) Способ лечени деструктивного панкреатита
SU1037683A1 (ru) Способ получени модифицированной урокиназы
JPH04501705A (ja) 腫瘍の組み合せ処理のためのフィブリン溶解剤の使用
Hartmeier Uses in Medicine
TH51752A (th) องค์ประกอบของยาร่วมฤทธิ์และวิธีการสำหรับการบำบัดรักษาการเจริญเติบโตของเนื้องอกหรือมะเร็ง และสำหรับทำให้การสร้างเม็ดเลือดกลับดีขึ้น หรือการเพิ่มเม็ดเลือด
UA29882A (uk) Спосіб лікування гострих тромбофлебітів нижніх кінцівок

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties